Financings in Brief: Atrix
This article was originally published in The Gray Sheet
Executive Summary
Atrix: Proposes to merge with Vipont Royalty Income Fund, Ltd. in a stock-swap transaction valued at $3.5 mil. Under terms of the deal, Fort Collins, Colorado-based development stage firm Atrix would exchange less than 9% of its 7.9 mil. outstanding shares for Vipont. Vipont, a funding vehicle formed in 1987, is jointly developing with Atrix the Atrigel injectable gel drug delivery system for use with the drug doxycycline to treat periodontal disease; Phase III trials are ongoing, a new drug application submission to FDA is anticipated in the first quarter of 1997. Atrix' second product, Atrisorb, is a guided tissue regeneration barrier for use in conjunction with gum surgery to promote tissue regeneration and treat periodontitis; a 510(k) submission is anticipated by year end. Vipont will approve or disapprove the plan Sept. 27...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.